Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estrogens and Parkinson's disease

D R Session1, M M Pearlstone, R Jewelewicz

  • 1Department of Obstetrics and Gynecology, Columbia-Presbyterian Medical Center, New York, New York 10032.

Medical Hypotheses
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated plasma norepinephrine inhibits insulin secretion, but adrenergic blockade reveals enhanced β-cell responsiveness in an ovine model of placental insufficiency at 0.7 of gestation.

Journal of developmental origins of health and disease·2013
Same author

Microsatellites behaving badly: empirical evaluation of genotyping errors and subsequent impacts on population studies.

Genetics and molecular research : GMR·2011
Same author

Controlled ovarian hyperstimulation: a review for the non-ART patient.

Minerva ginecologica·2011
Same author

Trisomic pregnancy and elevated FSH: implications for the oocyte pool hypothesis.

Human reproduction (Oxford, England)·2011
Same author

Induction of ovulation: current practice and prospects.

Bulletin of the New York Academy of Medicine·2009
Same author

Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2004

Estrogen may worsen Parkinsonian symptoms by affecting dopamine. A case study showed symptom improvement in a patient experiencing menopause due to leuprolide acetate, suggesting reduced estrogen benefits Parkinson's disease.

Area of Science:

  • Neuroendocrinology
  • Dopamine pathways
  • Movement disorders

Background:

  • Estrogens are known to modulate dopamine activity in the extrapyramidal system.
  • Clinical data on estrogen's effect on Parkinsonian symptoms are conflicting, with most suggesting worsening.
  • Estrogen therapy generally exacerbates Parkinsonism.

Observation:

  • A premenopausal patient with Parkinsonian symptoms experienced improvement while treated with leuprolide acetate.
  • Leuprolide acetate induces pharmacologic menopause, resulting in a hypoestrogenic state.

Findings:

  • The patient's Parkinsonian symptoms improved during the hypoestrogenic state induced by leuprolide acetate.
  • This suggests that a decrease in estrogen levels may alleviate Parkinson's disease symptoms.

Related Experiment Videos

Implications:

  • Estrogen's potential antidopaminergic effects on the nigrostriatal pathway might be responsible for worsening Parkinsonian symptoms.
  • Further research into estrogen's role in Parkinson's disease pathogenesis and potential therapeutic strategies targeting hormonal balance is warranted.